- Email: [email protected]
Corrigendum to “Jellyfish and other cnidarian envenomations cause pain by affecting TRPV1 channels” [FEBS Lett. 580 (2006) 5728–5732]
FEBS Letters 581 (2007) 1699
Corrigendum
Corrigendum to ‘‘Jellyfish and other cnidarian envenomations cause pain by affecting TRPV1 channels’’ [FEBS Lett. 580 (2006) 5728–5732]q Eva Cuypersa, Angel Yanagiharab, Evert Karlssonc, Jan Tytgata,* b
a Laboratorium voor Toxicologie, Campus Gasthuisberg, Herestraat 49, Bus 922, KULeuven B-3000, Belgium Be´ke´sy Laboratory of Neurobiology, Pacific Biosciences Research Center, University of Hawaii at Manoa, 1993 East West Road, Honolulu, HI 96822, USA c Lindsbergsgatan 11A, 752 40 Uppsala, Sweden
Available online 22 March 2007
A mistake occurred in the full chemical formula of compound BCTC, used in the in vivo studies. Full chemical name of BCTC should be N-(4-tertiarybutylphenyl)-4-(3-chloropyridin-2-yl)tetrahydropyrazine-1(2H)-carbox-amide. This compound was synthesized by Johnson & Johnson (Beerse, Belgium) and used in the animal facilities of Johnson & Johnson where rat studies were conducted. Ref. [21] should be replaced by the following: ‘‘N-(4-tertiarybutylphenyl)-4-(3-chloropyridin-2-yl)tetrahydropyrazine-1(2H)-carbox-amide (BCTC), a novel orally effective vanilloid receptor 1 antagonist with analgesic properties: I. In vitro characterization and pharmacokinetic properties’’ (article by Purdue Pharma).
q
DOI of original article: 10.1016/j.febslet.2006.09.030
* Corresponding author. Fax: +32 16 323 405. E-mail address: [email protected] (J. Tytgat).
0014-5793/$32.00 Ó 2007 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved. doi:10.1016/j.febslet.2007.03.036
Corrigendum
Corrigendum to ‘‘Jellyfish and other cnidarian envenomations cause pain by affecting TRPV1 channels’’ [FEBS Lett. 580 (2006) 5728–5732]q Eva Cuypersa, Angel Yanagiharab, Evert Karlssonc, Jan Tytgata,* b
a Laboratorium voor Toxicologie, Campus Gasthuisberg, Herestraat 49, Bus 922, KULeuven B-3000, Belgium Be´ke´sy Laboratory of Neurobiology, Pacific Biosciences Research Center, University of Hawaii at Manoa, 1993 East West Road, Honolulu, HI 96822, USA c Lindsbergsgatan 11A, 752 40 Uppsala, Sweden
Available online 22 March 2007
A mistake occurred in the full chemical formula of compound BCTC, used in the in vivo studies. Full chemical name of BCTC should be N-(4-tertiarybutylphenyl)-4-(3-chloropyridin-2-yl)tetrahydropyrazine-1(2H)-carbox-amide. This compound was synthesized by Johnson & Johnson (Beerse, Belgium) and used in the animal facilities of Johnson & Johnson where rat studies were conducted. Ref. [21] should be replaced by the following: ‘‘N-(4-tertiarybutylphenyl)-4-(3-chloropyridin-2-yl)tetrahydropyrazine-1(2H)-carbox-amide (BCTC), a novel orally effective vanilloid receptor 1 antagonist with analgesic properties: I. In vitro characterization and pharmacokinetic properties’’ (article by Purdue Pharma).
q
DOI of original article: 10.1016/j.febslet.2006.09.030
* Corresponding author. Fax: +32 16 323 405. E-mail address: [email protected] (J. Tytgat).
0014-5793/$32.00 Ó 2007 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved. doi:10.1016/j.febslet.2007.03.036